Figures computed from official regulatory filings — .
Ownershipinsiders 32.85% · institutions 0.07% · short 1.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CDT Equity Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
21 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Regan Andrew | OtherD (derivative) | $543.7 | SEC |
| Regan Andrew | Sell | n/a (No price was disclosed in the filing) | SEC |
| Regan Andrew | Other | n/a (No price was disclosed in the filing) | SEC |
| Regan Andrew | OtherD (derivative) | $543.7 | SEC |
| Taylor Mark Andrew | Sell | $829.1K | SEC |
| Taylor Mark Andrew | Sell | $3.8K | SEC |
| Taylor Mark Andrew | Sell | $2.1M | SEC |
| Taylor Mark Andrew | Sell | $3.5K | SEC |
| Regan Andrew | Award | $190K | SEC |
| Regan Andrew | OtherD (derivative) | $14.7 | SEC |
| Regan Andrew | Award | n/a (No price was disclosed in the filing) | SEC |
| Prospect Capital Securities Ltd | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prospect Capital Securities Ltd | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prospect Capital Securities Ltd | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prospect Capital Securities Ltd | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Farley Chele Chiavacci | AwardD (derivative) | $2M | Unusual size | SEC |
| Farley Chele Chiavacci | Award | $11K | SEC |
| Corvus Capital Ltd. | Award | $402.4K | SEC |
| Corvus Capital Ltd. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Regan Andrew | Award | $772.8K | SEC |
| Bligh James | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fry Simon Jeremy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fry Simon Jeremy | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Farley Chele Chiavacci | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Farley Chele Chiavacci | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |